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The objective of the study was to prospectively determine if body mass index (BMI) is predictive of live birth rates in patients
undergoing IVF. The prospective study enrolled 117 infertility patients with the primary outcome measure being IVF success
rates. Mean BMI did not diﬀer between patients with successful outcomes and those without successful outcomes. There was a
signiﬁcant positive correlation between BMI and the number of stimulated follicles (r = 0.19, P<. 05). A signiﬁcant negative
correlation between BMI and ampules of gonadotropins used (r =− 0.25, P<. 01) and between BMI and days of stimulation
(r =− 0.19, P<. 05) was noted. These data demonstrate that women with an elevated BMI produce more follicles, stimulate
quicker, and require less gonadotropins during IVF. However, BMI did not have a signiﬁcant eﬀect on pregnancy outcome rates.
1.Introduction
The published data regarding the eﬀect of body mass index
(BMI) on In Vitro Fertilization (IVF) cycles vary [1–13].
It has been proposed that extremes of BMI can aﬀect IVF
success rates [2, 13]. The extremes in body weight probably
aﬀect fecundity due to hormonal imbalances and ovulatory
dysfunction [3, 4]. The association of BMI and baseline
hormone levels has not been consistently demonstrated.
Most studies evaluating BMI are retrospective with limited
sample sizes and not designed to deﬁnitively demonstrate a
correlation with BMI and IVF success rates.
BMI, deﬁned as weight in kilograms divided by height
in meters squared (kg/m2), is a measure commonly used
to objectively assess obesity [14]. Excess weight (BMI ≥
25kg/m2) and obesity (BMI ≥ 30kg/m2) are known cont-
ributors to menstrual irregularities, anovulation, and infer-
tility; however, the eﬀect of being overweight on the success
of assisted reproductive treatment is less certain. The impact
of BMI on controlled ovarian hyperstimulation parameters,
such as amount of gonadotropins used, days of stimulation
needed, peak estradiol levels, number or quality of oocytes,
and pregnancy success is conﬂicting [1–13].
While many studies have demonstrated an association
between IVF stimulation parameters and BMI, few have
shown a signiﬁcant impact on IVF pregnancy outcomes
[2, 5, 7, 12]. We could ﬁnd only one prospective study
whose purpose was to evaluate the inﬂuence of BMI on
IVF pregnancy outcome [13]. Salha et al. in a matched
cohort design studied 100 patients and found that a BMI ≥
26kg/m2 wasassociatedwithahigherdoseofgonadotropins,
fewer oocytes, lower fertilization, and pregnancy rates [13].
Basedonthepublisheddata,wedesignedaprospectivestudy
to examine whether BMI is an accurate predictor of IVF
baseline values, stimulation parameters, and outcomes.
2.MaterialsandMethods
2.1. Population. Patients between the ages of 19 and 42
years were included independent of their diagnoses or prior
reproductive history. Because of the poor response docu-
mented in the literature, patients with elevated FSH levels2 ISRN Obstetrics and Gynecology
(≥12mIU/ml) and women >42 years of age were excluded
[15–17].AllwomenundergoingIVFatTriplerArmyMedical
Centerwhometinclusioncriteriawerecounseledandinvited
to participate in the study.
All patients received 35µg oral contraceptive pills for
21 to 35 days. During the last seven days of the oral cont-
raceptives, the patients were started on a GnRH-a (Lupron,
TAP Pharmaceuticals, North Chicago, IL) for a total of 14
days followed by stimulation with exogenous gonadotropins.
When the largest cohort of follicles reached the 16mm to 18
mm range, 10,000 units of human chorionic gonadotropin
(hCG) were administered. Transvaginal follicular aspiration
t o o kp l a c ei n3 5t o3 6h o u r sl a t e r .O np o s t r e t r i e v a ld a y3o r
5, embryos were transferred vaginally with abdominal ultra-
sound guidance using a Wallace transfer catheter (Cooper
Surgical, Shelton, CT).
The study protocol was approved by the human use
committee at Tripler Army Medical Center. Investigators
adhered to policies for protection of human subjects as
prescribed in 45CFR 46.
2.2. Experimental Design. The main outcome measure was
pregnancy outcome (pregnancy, cancellation, live birth,
and pregnancy loss) during IVF. BMI was calculated on
the patients’ baseline evaluation day after pituitary sup-
pression with oral contraceptives and prior to the start
of gonadotropin stimulation. Transvaginal ultrasound to
assess basal antral follicle number and ovarian volume was
performed on day 3 of the patient’s menstrual cycle the
month prior to IVF. All ultrasounds were performed by the
primary author (Frattarelli).
BMIwascomparedwithrespecttopatientage,diagnosis,
numberoffollicles,numberofoocytesretrieved,basalserum
labs (FSH, LH, and estradiol), peak estradiol level (deﬁned
as the level of estradiol on the day of human chorionic
gonadotropin administration), dehydroepiandrosterone sul-
fate (DHEAS), ampules of gonadotropins administered, days
of stimulation, and outcome rates (pregnancy, cancellation,
miscarriage, and live birth). All basal serum hormone
measurements were made during a nonmedicated cycle
within 3 months of initiation of the IVF cycle.
Pregnancy was conﬁrmed by a rising serum hCG at 4
weeks gestation followed by sonographic conﬁrmation of
cardiac activity at 6 weeks gestation. Patients were canceled
for failing to produce ≥3 expanding follicles or failure
to respond to gonadotropins with an adequate estradiol
response of at least 300pg/ml.
2.3. Laboratory Assays. The LH, FSH, Estradiol (E2), and
Testosterone assays were all done with the Advia Centaur
chemiluminescence system (Bayer Diagnostics, Tarrytown,
New York). The inter- and intra-assay coeﬃcients of varia-
t i o nw e r ef r o m2 . 0t o2 . 9 %a n df r o m0 . 3t o2 . 7 %f o rF S H ,
from 3.2 to 3.0% and from 1.5 to 2.9% for LH, from 5.3 to
11.3% and from 4.6 to 6.7% for E2, from 2.3 to 6.2% and
from 1.4 to 4.7% for testosterone. The radioimmunoassay
used for Androstenedione (Esoterix Inc., Austin, Texas)
had inter- and intra-assay coeﬃcients of variation from
3.0 to 4.6% and from 6.2 to 10.8%. The DHEAS assay
was performed using an Immulite immunoassay (Diagnostic
Product Corporation, Los Angeles, California). The inter-
and intra-assay coeﬃcients of variation for DHEAS were
20% for each.
2.4. Statistical Analysis. B a s e do no u rp r e v i o u sr e t r o s p e c t i v e
study, controlling for probability of a Type 1 error at alpha =
0.05 and a power of 0.80, a sample of 90 patients would be
able to detect a 10% diﬀerence in mean BMI among patients
who are either successful or unsuccessful in their pregnancy
attempt during IVF [1]. To allow for cancellations and drop
outs, 118 patients were scheduled to be consented for the
protocol.
For normally distributed data, a t-test was used to
compare the mean values between two groups. For data
that were not normally distributed, a Mann-Whitney rank
sum test was used to compare the mean values between two
groups. A Kruskal-Wallis one-way analysis of variance on
rankswasusedtocompareoutcomesamongmultiplegroups
whose data were not normally distributed. Dunn’s method
was used for pairwise multiple comparison. Diﬀerences in
outcome rates were analyzed using a Chi-square or two-
tailed Fishers exact test where appropriate. Linear regression
analysis assessed the correlation between linear data.
Patients were grouped by BMI beginning at <20kg/m2
and extending to ≥40kg/m2 at increments of 1kg/m2.T h e
clinical outcome rates (implantation rate, pregnancy rate,
miscarriage rate, and live birth rate) were then calculated
for each increment. The clinical outcome rates were then
evaluatedwithreceiver-operatorcharacteristic (ROC) curves
to determine if there was an obvious break point or
threshold at which there was a signiﬁcant change in outcome
rates. Contingency table analyses were used to evaluate the
outcome rates above and below the selected threshold value.
An alpha error of 0.05 was considered signiﬁcant for all
comparisons. Relative risk and 95% conﬁdence intervals are
displayed where appropriate. All data are reported as means
with their associated standard deviations.
3. Results
One hundred seventeen women undergoing 117IVF cycles
met inclusion criteria and were counseled, consented, and
included in the study. No patients were lost to followup
or dropped out of the study. Patients enrolled had the
following primary etiologies and associated BMI for their
infertility: tubal factor (26%) (BMI = 26.8 ± 4.6kg/m 2),
anovulation (20%) (BMI = 27.2 ± 6.3kg/m 2), unexplained
infertility (18%) (BMI = 26.6 ± 6.0kg/m 2), male factor
(17%) (BMI = 25.7 ± 3.9kg/m 2), endometriosis (9%)
(BMI = 24.8 ± 5.1kg/m 2), diminished ovarian reserve (6%)
(BMI = 23.9 ± 5.4kg/m 2), and uterine factor (4%) (BMI =
26.2 ± 4.9kg/m 2). BMI did not diﬀer based on primary
etiology (P = .45).
Table 1 summarizes the demographics and the prestimu-
lation characteristics of the patient population. Table 2 sum-
marizes the stimulation characteristics and IVF cycle out-
comes of the patient population. The data were subdivided
to evaluate the impact of overweight (BMI ≥ 25kg/m2)a n dISRN Obstetrics and Gynecology 3
Table 1: Demographics and Prestimulation IVF cycle Characteristics. Results are given as mean values with their associated standard
deviations for all patients in the study, patients with BMI < 25kg/m2 compared to patients with BMI ≥ 25kg/m2, and patients with
BMI < 30kg/m2 compared to patients with BMI ≥ 30kg/m2.
All patients
N = 117
BMI < 25kg/m2
N = 58
BMI ≥ 25kg/m2
N = 59 P value BMI < 30kg/m2
N = 96
BMI ≥ 30kg/m2
N = 21 P value
Age 33.7 ±4.13 4 .1 ± 4.23 3 .3 ±4.0 .30 33.8 ±4.13 3 .1 ±4.1. 4 4
D3 FSH (mIU/mL) 5.5 ±1.75 .7 ±1.55 .3 ±1.9 .21 5.5 ±1.75 .5 ±1.9. 9 5
D3 LH (mIU/mL) 5.3 ±2.85 .2 ±2.45 .4 ±3.1 .90 5.3 ±2.75 .4 ±3.1. 7 9
Androstenedione (ng/dL) 95.3 ±50.18 8 .2 ±49.9 102.7 ±50.4 .32 96.8 ±48.08 6 .4 ±65.5. 6 1
DHEAS (ug/dL) 173.0 ±96.9 166.9 ± 90.8 179.0 ±103.0 .48 171.3 ±89.4 181.2 ±129.3. 8 6
Testosterone (ng/dL) 43.0 ±18.94 0 .3 ±16.54 5 .8 ±20.7 .12 41.2 ±16.55 1 .6 ±26.3. 1 4
Number of Antral follicles 20.6 ±12.71 7 .5 ±10.02 4 .2 ±14.1 <.05
∗ 19.7 ±11.72 4 .6 ±14.7. 1 7
Total Ovarian volume
(cm3) 13.4 ±6.41 2 .8 ± 6.41 3 .9 ±3.3 .48 13.1 ±6.41 4 .6 ±6.7. 3 8
∗Signiﬁcant P values (≤.05).
Table 2: IVF Stimulation Characteristics and IVF outcomes. Results are given as mean values with their associated standard deviations for
all patients in the study, patients with BMI < 25kg/m2 compared to patients with BMI ≥ 25kg/m2, and patients with BMI < 30kg/m2
compared to patients with BMI ≥ 30kg/m2.
All patients
N = 117
BMI < 25kg/m2
N = 58
BMI ≥ 25kg/m2
N = 59 P value BMI < 30kg/m2
N = 96
BMI ≥ 30kg/m2
N = 21 P value
Peak estradiol (pg/mL) 2774.6±1933.9 2476.7 ±1866.7 3089.4 ±1970.9 <.05
∗ 2690.8 ±1773.3 3171.6 ±2586.6. 6 1
Ampules of gonadotropins 55.9 ±11.85 9 .3 ±10.95 2 .3 ±11.8 <.001
∗ 56.8 ±11.75 1 .9 ±12.1. 1 3
Days of stimulation 10.1 ±1.31 0 .4 ±12.29 .7 ±1.3 <.001
∗ 10.1 ±1.41 0 .0 ±1.0. 4 5
Number of follicles 18.9 ±11.61 6 .1 ±10.32 1 .9 ±12.1 <.01
∗ 17.8 ±10.32 4 .3 ±15.5. 1 2
Number of oocytes 16.7 ±11.91 5 .5 ±11.11 8 .1 ±12.6 .21 16.3 ±11.51 9 .0 ±14.0. 5 6
Number of mature oocytes 13.2 ±8.91 2 .4 ± 8.91 4 .1 ±9.0 .24 13.1 ±8.91 3 .8 ±9.3. 8 5
Number of embryos 10.4 ±7.89 .6 ±7.41 1 .3 ±8.2 .18 10.4 ±7.91 0 .8 ±7.8. 8 3
Number of embryos
transferred 2.9 ±0.93 .0 ±0.92 .9 ±1.0. 5 42 .9 ±0.92 .9 ±0.9. 8 0
Day of embryo transfer 3.6 ±1.13 .6 ±1.13 .6 ±1.1. 9 33 .7 ±1.13 .2 ±1.0. 1 9
Pregnancy rate (%) 50.4% 48.3% 52.5% .64 52.1% 38.1% .30
Implantation rate (%) 26.5% 22.6% 30.7% .10 25.7% 28.6% .65
∗Signiﬁcant P values (≤.05).
obesity (BMI ≥ 30kg/m2) on prestimulation parameters,
stimulation parameters, and IVF outcome. When evaluating
the overweight population, a signiﬁcant diﬀerence was noted
in the number of antral follicles, peak estradiol levels,
ampules of gonadotropins used for stimulation, number of
days of stimulation, and number of follicles. No signiﬁcant
diﬀerence was noted for any parameter when evaluating the
obese patient population.
TheBMIofthestudypopulationrangedfrom18.6kg/m2
to 43.9kg/m2 with a mean of 26.1 ± 4.8kg/m 2. Using linear
regression analysis, BMI was compared to the demographics,
pre- and poststimulation parameters. The results showed
a signiﬁcant positive relationship between BMI and the
number of follicles noted by ultrasound prior to egg retrieval
(r = 0.19, P<. 05). A signiﬁcant negative correlation
between BMI and ampules used (r =− 0.25, P<. 01)
and between BMI and days of stimulation (r =− 0.19,
P<. 05) was noted. The correlation with other pre- and
poststimulation parameters was not statistically signiﬁcant.
Thisstudywaspoweredtodetecta10%diﬀerenceinBMI
when evaluating pregnancy outcome. We examined the data
by comparing the BMI of those who were able to achieve the
outcome measure of pregnancy (BMI = 26.0 ± 4.6kg/m 2)
compared to those not pregnant (BMI = 26.2 ± 5.1kg/m 2),
no signiﬁcant diﬀerence in BMI was noted. After grouping
thepatientsbyBMIbeginningat<20kg/m2 andextendingto
≥40kg/m2 atincrementsof1kg/m2,thresholdanalysisusing
contingency tables failed to identify any signiﬁcant change
in outcome rates at any of the BMI values. Outcome rates
did not signiﬁcantly diﬀer according to BMI (Figure 1). ROC
curves demonstrated an area under the curve of 0.53 (0.39,
0.63) for implantation rates, 0.50 (0.40, 0.61) for pregnancy
rates, and 0.46 (0.29, 0.64) for miscarriage rates.
Power analysis revealed that 4,169 patients would be
needed to establish a statistical signiﬁcance for BMI of
< or ≥25kg/m2 and pregnancy rates. While a change in
pregnancy rates from 52.1% with a BMI < 30kg/m2 to
38.1% with a BMI ≥ 30kg/m2 is clinically signiﬁcant,4 ISRN Obstetrics and Gynecology
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Figure 1: IVF outcome rates (Implantation, Pregnancy, Live Birth)
for the entire patient population (ALL) and for the diﬀerent subsets
of the IVF population. The subsets are divided into thin (BMI <
20kg/m2), normal weight (BMI = 20 to 24.9kg/m2), overweight
(BMI 25 to 29.9kg/m2), and obese (BMI ≥ 30kg/m2). Using
contingency table analysis and receiver-operator characteristic
curves, no signiﬁcant threshold value was noted for outcome rates
throughout the entire data range.
a power analysis revealed that 659 patients would be needed
to establish a statistical signiﬁcance.
4. Discussion
This study conﬁrms the diﬃculty in establishing the eﬀect
of BMI on in vitro fertilization. With a prospective cohort
design, we attempted to determine if mean BMI diﬀered
between patients with successful and unsuccessful IVF
outcomes. We also evaluated the correlation of BMI to
baseline and stimulation parameters during IVF.
Unlike some previous studies, which found it more
diﬃcult to stimulate follicular development in patients with
an elevated BMI as demonstrated by an increase in number
of days or ampules of gonadotropins required, our data
demonstrated that fewer ampules of medication and days
of stimulation were needed with increasing BMI [4–7].
These results suggest that as BMI increases, the amount of
gonadotropins and days of stimulation decrease while the
number of follicles produced increases.
If our ﬁndings hold true, one might expect an increase
in pregnancy rates. However, an increase in pregnancy rates
wasnot realizedinthisstudy.Infact,thesubanalysisofobese
patients (BMI ≥ 25kg/m2) suggested that clinically obese
patients may experience a decrease in pregnancy rates. This
ﬁnding is consistent with the results from previous studies
[2, 5, 7, 13].
Salha et al. also prospectively evaluated BMI and patient
outcome in IVF cycles and found that a BMI ≥ 26kg/m2
was associated with a higher dose of gonadotropins, fewer
oocytes, and lower fertilization and pregnancy rates [14].
Our data suggest that a lower dose of gonadotropins, more
oocytes, and lower pregnancy rates are seen in patients with
an elevated BMI. A possible explanation for the diﬀerences
seen between the various studies could be the diﬀerent
subdivisions of BMI that have been used in studies to stratify
patients. Previous studies have used up to ﬁve subdivisions
of BMI; likewise, diﬀerent deﬁnitions of obesity have been
used (BMI > 25kg/m2 versus BMI > 27kg/m2)a n dav a r i e t y
of diﬀerent IVF induction protocols were used [2, 4, 5]. Our
study looked at the entire range of BMI values in order to
ﬁnd a threshold value.
There are many strengths of this study. The most
prominent is the use of prospective cohort design. Therefore,
ascertainment and recall bias were minimized. No patients
werelosttofollowupordroppedoutofthestudy.Allpatients
were included in the data analysis. All patients received the
same GnRH-agonist protocol. Unlike the prior studies, we
used threshold analysis to deﬁne a scientiﬁc cutoﬀ point
that would be predictive of success or failure. This use
of threshold analysis decreases the bias that is found in
arbitrarily choosing a BMI at which to study patients.
In summary, these data demonstrate that an increase
in BMI may be associated with the need for fewer days
of stimulation, fewer ampules of medication, and a greater
number of follicles produced. Although BMI was associated
with the named IVF stimulation parameters, BMI does not
seem to signiﬁcantly aﬀect pregnancy outcome rates.
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